ImmuCell Corporation (FRA:IUL)
Germany · Delayed Price · Currency is EUR | Market Cap | 78.11M +66.2% |
| Revenue (ttm) | 26.85M +8.5% |
| Net Income | 689.19K -55.3% |
| EPS | 0.07 -62.8% |
| Shares Out | n/a |
| PE Ratio | 113.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 8.55 |
| Previous Close | 8.40 |
| Day's Range | 8.55 - 8.55 |
| 52-Week Range | 3.88 - 10.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mast... [Read more]
Financial Performance
In 2025, ImmuCell's revenue was $27.64 million, an increase of 4.34% compared to the previous year's $26.49 million. Losses were -$1.04 million, -51.78% less than in 2024.
Financial numbers in USD Financial StatementsNews
ImmuCell Earnings Call Transcript: Q2 2026
Second quarter 2026 saw 11.5% sales growth and strong domestic performance, offset by lower international sales. Gross margin declined due to cost shifts and lower output, but net income and adjusted EBITDA rose sharply, aided by a $2M legal settlement.
ImmuCell Earnings release: Q2 2026
ImmuCell released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
ImmuCell Quarterly report: Q2 2026
ImmuCell has published its Q2 2026 quarterly earnings report on August 14, 2026.
ImmuCell Slides: Q2 2026
ImmuCell has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets product...
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets product...
Immucell reports preliminary Q2 revenue $7.2M
“Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase…
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets product...
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
ImmuCell Transcript: AGM 2026
The meeting confirmed a quorum and approved all proposals, including director elections, executive compensation, a new stock plan, a charter amendment, and auditor ratification. A major two-phase manufacturing expansion was announced to support sustained product demand and growth.
ImmuCell Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue and net income growth driven by strong Tri-Shield sales, margin expansion, and increased U.S. market share. Capacity and sales force investments support continued growth, with international expansion and plant upgrades underway.
ImmuCell Quarterly report: Q1 2026
ImmuCell has published its Q1 2026 quarterly earnings report on May 15, 2026.
ImmuCell Earnings release: Q1 2026
ImmuCell released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
ImmuCell Slides: Q1 2026
ImmuCell has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 15, 2026.
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ca...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ca...
ImmuCell Proxy statement: Proxy filing
ImmuCell filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
ImmuCell Proxy statement: Proxy filing
ImmuCell filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve ...
ImmuCell Slides: Investor presentation
ImmuCell has posted slides in relation to its latest quarterly earnings report, which was published on April 13, 2026.
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets produc...
ImmuCell Earnings Call Transcript: Q4 2025
2025 saw 4.3% sales growth to $27.6M, gross margin rise to 41%, and a $3.3M operating income swing, driven by expanded capacity and a strategic focus on First Defense. Net loss narrowed to $1M despite significant non-cash write-downs.